Selection of maintenance therapy during first-line treatment of advanced ovarian cancer based on pharmacologic characteristics.
Hidekatsu NakaiNoriomi MatsumuraPublished in: Expert opinion on pharmacotherapy (2023)
In patients with homologous recombination deficiency and no macroscopic residual disease (R0) after primary debulking surgery (PDS), the combination of bevacizumab plus olaparib seems to be the best regimen. Olaparib monotherapy is suitable for patients with BRCA mutations other than PDS R0. Bevacizumab is most useful in cases with a short duration of the rebound effect, i.e. short survival. Niraparib is useful in others but may be more useful in Asians.
Keyphrases
- dna repair
- dna damage
- metastatic colorectal cancer
- minimally invasive
- neoadjuvant chemotherapy
- coronary artery bypass
- combination therapy
- open label
- randomized controlled trial
- replacement therapy
- surgical site infection
- radiation therapy
- stem cells
- atrial fibrillation
- mesenchymal stem cells
- bone marrow
- percutaneous coronary intervention
- smoking cessation
- study protocol